OMKARCHEM - Omkar Spl.Chem.
📢 Recent Corporate Announcements
Omkar Speciality Chemicals has announced April 29, 2026, as the record date for the total extinguishment and cancellation of its existing paid-up share capital. This action is being taken pursuant to a Resolution Plan approved by the NCLT Mumbai bench on July 31, 2025, under the Insolvency and Bankruptcy Code. The cancellation applies to all equity shares of INR 10 each held by both the Promoters and the Public Shareholders. Consequently, existing equity holders will see their investment value reduced to zero as the shares are wiped out.
- Record date for share cancellation fixed as April 29, 2026.
- 100% of equity shares held by Promoters and Public Shareholders will be extinguished.
- The move follows the NCLT order dated July 31, 2025, approving the Resolution Plan.
- Company has been under the Corporate Insolvency Resolution Process (CIRP) since December 5, 2022.
Omkar Speciality Chemicals is implementing its NCLT-approved resolution plan, which mandates the 100% extinguishment of all existing promoter and public equity shares. The record date for this cancellation is fixed for April 29, 2026, meaning current shareholders will lose their entire holdings with no mentioned compensation. To restart operations under new ownership, the company will issue 50 lakh new shares to IFFAS Kshitij SPV LLP for ₹5 crore. Furthermore, it has approved a ₹20 crore loan from Kshitij Polyline Limited and appointed a new CFO and Company Secretary to lead the restructured entity.
- 100% of existing promoter and public equity shares to be cancelled/extinguished on the record date of April 29, 2026.
- Issuance of 50,00,000 new equity shares at ₹10 each to IFFAS Kshitij SPV LLP for a total of ₹5 crore.
- Approval to raise a loan of up to ₹20 crore from Kshitij Polyline Limited to fund the resolution plan.
- Treatment of Earnest Money Deposit as debt/loan forming part of the ₹21.90 crore funding requirement.
- Appointment of Mahendra Kumar Jain as CFO and Kuldeep Menaria as Company Secretary and Compliance Officer.
Omkar Speciality Chemicals, which has been under the Corporate Insolvency Resolution Process (CIRP) since December 2022, has issued a clarification regarding its upcoming Monitoring Committee meeting. The company stated that April 15, 2026, will not be the record date as previously suggested, but rather the date on which the record date will be decided. The finalized record date will comply with regulatory requirements, ensuring a minimum gap of seven working days from the meeting date. This update is part of the ongoing resolution process overseen by the Monitoring Committee.
- Clarified that April 15, 2026, is the meeting date and not the record date for corporate actions.
- The revised record date will be determined during the Monitoring Committee meeting on April 15, 2026.
- The record date will maintain a mandatory minimum gap of 7 working days from the meeting date.
- Company remains under Corporate Insolvency Resolution Process (CIRP) since the December 5, 2022, order.
Omkar Speciality Chemicals is proceeding with its NCLT-approved Resolution Plan, which involves the total extinguishment of all existing promoter and public equity shares. A Monitoring Committee meeting on April 15, 2026, will finalize the record date for this cancellation, effectively wiping out current shareholders. Following the wipe-out, the company will issue 5,000,000 new equity shares at ₹10 each to raise ₹5 crore through a private placement. The company is also restructuring its leadership with the appointment of a new CFO and Company Secretary.
- 100% extinguishment of all existing equity shares held by both Promoters and Public shareholders
- Record date for share cancellation to be determined at the Monitoring Committee meeting on April 15, 2026
- Issuance of 50,00,000 new equity shares at ₹10 each for an aggregate of ₹5,00,00,000
- Appointment of Mahendra Kumar Jain as CFO and Kuldeep Menaria as Company Secretary
Financial Performance
Revenue Growth by Segment
Total revenue grew 7% YoY to INR 86 Cr in Q1 FY18. The Pharmaceutical segment contributes 76% of revenue (down from 82-85% historically), while newly launched Fragrances and Food segments currently contribute 1-2% with a target to reach 10% as operations scale.
Geographic Revenue Split
Domestic sales account for approximately 80% of total revenue, while Exports contribute 20% across 38 countries including Europe, North America, China, and other Asian markets.
Profitability Margins
Gross margins for new products are targeted at 32-35%. Net profit grew 38% YoY to INR 7.6 Cr in Q1 FY18, driven by a shift toward higher-margin niche products and reduced interest costs.
EBITDA Margin
EBITDA margin stood at 17% in Q1 FY18, an improvement from approximately 15% in the previous year. Management targets a consistent EBITDA margin range of 17-18% based on optimized product mix and fungible manufacturing capacities.
Capital Expenditure
The company completed a major CAPEX cycle in FY17, increasing capacity by 800 MTPA. Future requirements are limited to maintenance CAPEX of approximately INR 4 Cr to 5 Cr per annum.
Credit Rating & Borrowing
The company is focused on debt reduction, repaying approximately INR 5 Cr to 6 Cr per quarter. High-cost debt has been largely repaid using proceeds from promoter stake sales to lower the overall interest burden.
Operational Drivers
Raw Materials
Not disclosed in available documents; however, the company utilizes specialized catalysts for its 200+ product portfolio.
Capacity Expansion
Current capacity was recently expanded by 800 MTPA through previous year's CAPEX. The company operates 5 manufacturing units and 1 R&D center to support its 200+ product range.
Raw Material Costs
Not disclosed as a specific percentage of revenue, but the company uses catalyst-driven processes to ensure higher yields and better customized products, which helps protect the 32-35% gross margin range.
Manufacturing Efficiency
The company employs in-house, multiproduct manufacturing facilities with catalyst-driven processes to ensure higher yields and customized product specifications.
Logistics & Distribution
The company exports to 38 countries; distribution is handled through a mix of direct supply to formulators and a network of distributors to manage credit risk.
Strategic Growth
Expected Growth Rate
15%
Growth Strategy
Growth will be achieved by diversifying the revenue base to reduce pharmaceutical dependence to 70%, scaling the newly launched Fragrance and Food segments to a 10% revenue share, and expanding export footprints in regulated markets. The company leverages its 17-18 patent filings and pioneer status in niche molecules to maintain high entry barriers.
Products & Services
Specialty chemicals including niche molecules for pharmaceuticals, glass, cosmetics, ceramics, cattle and poultry feeds, fragrances, flavors, and nutraceuticals.
Brand Portfolio
Omkar Speciality Chemicals; Lasa Supergenerics (demerged entity).
New Products/Services
Recently launched Fragrance and Food additives are expected to grow from 1-2% to 10% of total revenue contribution.
Market Expansion
Targeting increased export penetration beyond the current 20% share, focusing on 38 existing countries including North America and Europe.
Market Share & Ranking
Pioneer and one of the only manufacturers of many niche products in India; global market size for its new product segments is estimated at INR 500-600 Cr.
Strategic Alliances
The company underwent a demerger of its subsidiary, Lasa Supergenerics, which is now led independently by Omkar Herlekar to allow both entities to focus on specific growth opportunities.
External Factors
Industry Trends
The specialty chemicals industry is shifting toward high-quality customized products. While the pharma sector faces temporary regulatory headwinds, long-term demand remains robust due to population growth and lifestyle changes. Omkar is positioning itself by diversifying into FMCG and fragrance segments.
Competitive Landscape
Limited global competition in specific niche molecules; however, the company faces broader competition in the general pharmaceutical intermediate space.
Competitive Moat
The moat is sustained by pioneer status in niche products, patented catalyst-driven processes, and high entry barriers due to complex regulatory approval requirements. These factors protect the 17-18% EBITDA margins.
Macro Economic Sensitivity
The pharma sector is sensitive to US FDA regulatory changes, which impacts approximately 76% of the company's current business.
Consumer Behavior
Increased demand for nutraceuticals, fragrances, and food additives is driving the company's diversification strategy.
Geopolitical Risks
Trade barriers in regulated markets like Europe and North America could impact the 20% export revenue stream.
Regulatory & Governance
Industry Regulations
Operations are subject to US FDA regulatory standards for pharmaceutical clients and NCLT monitoring under the Insolvency and Bankruptcy Code (IBC) 2016.
Legal Contingencies
The company was subject to a Corporate Insolvency Resolution Process. A Resolution Plan was approved by the NCLT Mumbai Bench on July 31, 2025. A Monitoring Committee was established with its first meeting held on August 13, 2025, to oversee the implementation of the approved plan.
Risk Analysis
Key Uncertainties
The primary uncertainty is the successful implementation of the NCLT-approved Resolution Plan and the potential for further regulatory hurdles in the pharmaceutical sector impacting 76% of revenue.
Geographic Concentration Risk
80% of revenue is concentrated in the Indian domestic market, making the company vulnerable to local economic and regulatory shifts.
Third Party Dependencies
Dependency on distributors for sales in high-risk payment areas to mitigate credit risk.
Technology Obsolescence Risk
The company mitigates technology risk through its dedicated R&D center and focus on patented catalyst processes for niche molecules.
Credit & Counterparty Risk
The company manages credit exposure by shifting to shorter payment cycles (30 days) for new products and using distributors to handle collections from certain pharma clients.